Human Langerin/CD207 Alexa Fluor® 350-conjugated Antibody
Human Langerin/CD207 Alexa Fluor® 350-conjugated Antibody Summary
Tyr64-Pro328
Accession # Q9UJ71
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
Background: Langerin/CD207
Langerin (also known as CD207) is a type II transmembrane glycoprotein which is member K of the C-type lectin domain family 4 (1). Langerin is used as a marker for Langerhans cells (LCs) which represent the immature dendritic cells in the epidermis (1, 2). LCs uniquely contain “tennis racket”-shaped endosomal recycling compartment subdomains with pentalamellar membranes termed Birbeck granules (1‑3). Langerin is necessary and sufficient for Birbeck granule formation (1). The 328 amino acid (aa) human langerin sequence contains a 43 aa cytoplasmic domain, a 21 aa transmembrane domain and a 264 aa extracellular domain (ECD) that contains a coiled-coil domain and a single C-type lectin domain. Trimerization greatly increases the lectin binding affinity (4). Langerin internalizes endogenous proteins such as type I procollagen. Internalization by LC is thought to lead to suppression of self reactions (4‑6). Langerin also mediates endocytosis of non‑peptide antigens containing mannose, N-acetyl glucosamine and fucose that are expressed by mycobacteria and fungae (4, 7). Some antigens, such as the M. leprae glycolipid arabinomycolate, are ultimately presented by human LC CD1a in cutaneous-draining lymph nodes (8). Langerin performs a barrier-like function to HIV-1 transmission due to its internalization of virus particles for destruction (9). A rare human polymorphism within the lectin domain, W264R, abolishes both carbohydrate recognition and Birbeck granule formation (10, 11). Genetic deletion of mouse langerin was not shown to have functional consequence other than abolishing Birbeck granule formation (12). Human langerin shares 68%, 62%, 71% aa identity with mouse, rat and bovine langerin ECD, respectively.
- Valladeau, J. et al. (2000) Immunity 12:71.
- Valladeau, J. et al. (2003) Immunol. Res. 28:93.
- McDermott, R. et al. (2002) Mol. Biol. Cell 13:317.
- Stambach, N. S. and M. E. Taylor (2003) Glycobiology 13:401.
- Tada, Y. et al. (2006) J. Invest. Dermatol. 126:1549.
- Ritter, U. and A. Osterloh (2007) Med. Microbiol. Immunol. 196:51.
- Takahara, K. et al. (2003) Int. Immunol. 16:819.
- Hunger, R. E. et al. (2004) J. Clin. Invest. 113:701.
- De Witte, L. et al. (2007) Nat. Med. 13:367.
- Verdijk, P. et al. (2005) J. Invest. Dermatol. 124:714.
- Ward, E. M. et al. (2006) J. Biol. Chem. 281:15450.
- Kissenpfennig, A. et al. (2005) Mol. Cell. Biol. 25:88.
Product Datasheets
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human Langerin/CD207 Alexa Fluor® 350-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human Langerin/CD207 Alexa Fluor® 350-conjugated Antibody and earn rewards!
Have you used Human Langerin/CD207 Alexa Fluor® 350-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
